H1‐antihistamines for primary mast cell activation syndromes (MCAS): a systematic review
ConclusionsThere is an urgent need for large, well‐designed, double‐blind, placebo‐controlled randomized trials investigating the effectiveness, cost‐effectiveness and safety of second‐generation H1‐antihistamines in treatment of primary MCAS.This article is protected by copyright. All rights reserved. (Source: Allergy)
Source: Allergy - January 1, 2015 Category: Allergy & Immunology Authors: Ulugbek B. Nurmatov, Edmund Rhatigan, F. Estelle R. Simons, Aziz Sheikh Tags: Review Source Type: research
Can Improved Treatment of Allergic Rhinitis Improve Workplace Productivity? The Role of Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate (Dymista)
Allergic rhinitis (AR) affects 10-20% of the US population, with treatment costs exceeding $6 billion annually and has been shown to have a substantial impact on productivity. In the U. S. AR is estimated to result in 3.5 million lost work days and 2 million lost school days annually. AZ/FP is an intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system indicated for the relief of symptoms of seasonal AR (SAR). Patients treated with AZ/FP experience significantly greater and faster symptom relief in comparison to first-line therapy in trials, and thus have the potential to...
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: B. Harrow, J. Hofmeister, L.N. Gever, J. Karafilidis, M.J. Lacey, C.M. Scheibling, J.E. Schneider Source Type: research
Stability Study of the Antihistamine Drug Azelastine HCl along with a Kinetic Investigation and the Identification of New Degradation Products.
Abstract
The first stability-indicating HPLC method was developed and validated for azelastine HCl (AZL). The separation of AZL from its degradation products was achieved on a C18 column using acetonitrile-0.04 M phosphate buffer of pH 3.5 (32:68, v/v) as a mobile phase with UV-detection at 210 nm and naftazone as an internal standard. The method was rectilinear over the range of 0.2 - 20.0 μg mL(-1) with a detection limit of 7.05 ng mL(-1). The degradation behavior of AZL was studied under different ICH-recommended stress conditions along with a kinetic investigation; also, degradation products were iden...
Source: Analytical Sciences : the international journal of the Japan Society for Analytical Chemistry - June 14, 2014 Category: Chemistry Authors: El-Shaheny RN, Yamada K Tags: Anal Sci Source Type: research
In silico analysis and experimental validation of azelastine hydrochloride (N4) targeting sodium taurocholate co‐transporting polypeptide (NTCP) in HBV therapy
ConclusionsIn silico analysis and experimental validation together demonstrated that compound N4 can target NTCP in HepG2.2.15 cells, which may shed light on exploring it as a potential anti‐HBV drug. (Source: Cell Proliferation)
Source: Cell Proliferation - June 1, 2014 Category: Cytology Authors: L.‐L. Fu, J. Liu, Y Chen, F.‐T. Wang, X. Wen, H.‐Q. Liu, M.‐Y. Wang, L. Ouyang, J. Huang, J.‐K. Bao, Y.‐Q. Wei Tags: Original Article Source Type: research
Azelastine desensitization of transient receptor potential vanilloid 1: A potential mechanism explaining its therapeutic effect in nonallergic rhinitis.
CONCLUSION: Azelastine, similar to capsaicin, exhibits direct activity on TRPV1 ion channels that may represent a novel mechanistic pathway explaining its clinical efficacy in NAR.
PMID: 24980233 [PubMed - in process] (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - May 1, 2014 Category: ENT & OMF Authors: Singh U, Bernstein JA, Haar L, Luther K, Jones WK Tags: Am J Rhinol Allergy Source Type: research
Effect of intranasal azelastine on substance P release in perennial nonallergic rhinitis patients.
CONCLUSION: Azelastine intranasal spray reduces SP release into nasal lavage fluid of NAR patients immediately after hypertonic nasal saline challenge. Reduction of neuropeptide release may be an important aspect of the clinical efficacy of topical azelastine in perennial NAR patients.
PMID: 24274229 [PubMed - in process] (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - November 1, 2013 Category: ENT & OMF Authors: Gawlik R, Jawor B, Rogala B, Parzynski S, Dubuske L Tags: Am J Rhinol Allergy Source Type: research
Virtual screening using the ligand ZINC database for novel lipoxygenase-3 inhibitors.
Abstract
The leukotrienes constitute a group of arachidonic acid-derived compounds with biologic activities suggesting important roles in inflammation and immediate hypersensitivity. Epidermis-type lipoxygenase-3 (ALOXE3), a distinct subclass within the multigene family of mammalian lipoxygenases, is a novel isoenzyme involved in the metabolism of leukotrienes and plays a very important role in skin barrier functions. Lipoxygenase selective inhibitors such as azelastine and zileuton are currently used to reduce inflammatory response. Nausea, pharyngolaryngeal pain, headache, nasal burning and somnolence ar...
Source: Bioinformation - August 1, 2013 Category: Bioinformatics Authors: Monika, Kour J, Singh K Tags: Bioinformation Source Type: research
Efficacy and Safety of Azelastine and Levocetirizine in Allergic Rhinitis
(Gian Sagar Medical College and Hospital, Patiala, India) (Original Article; p143-147) (Source: Journal of Pakistan Medical Students)
Source: Journal of Pakistan Medical Students - July 2, 2013 Category: Universities & Medical Training Authors: JPMS Source Type: research
Intranasal phototherapy versus azelastine in the treatment of seasonal allergic rhinitis
Conclusion: Whether intranasal phototheraphy will be a standard treatment of SAR or not should be appraised in future studies and clinical trials. (Source: Auris, Nasus, Larynx)
Source: Auris, Nasus, Larynx - June 11, 2013 Category: ENT & OMF Authors: Silviu Albu, Sorin Baschir Tags: Rhinology Source Type: research
Dymista: first steroid plus antihistamine nasal spray
Abstract
Dymista is a new nasal spray containing fluticasone and azelastine. Our New products review considers the trial evidence for its efficacy and side‐effects and suggests its potential role in the treatment of allergic rhinitis. (Source: Prescriber)
Source: Prescriber - May 22, 2013 Category: Primary Care Authors: Steve Chaplin Tags: New products Source Type: research
Efficacy and Safety of Azelastine and Levocetirizine in Allergic Rhinitis
Authors: Surbhi Mahajan1, Vipan Gupta2, Ashwani K Gupta3, Prithpal S Matreja3, Amandeep Singh3, PML Khanna4, Sunder Singh5Affiliations: 1 MBBS Student, Gian Sagar Medical College and Hospital,…The postEfficacy and Safety of Azelastine and Levocetirizine in Allergic Rhinitis appeared first onJPMS. (Source: Journal of Pakistan Medical Students)
Source: Journal of Pakistan Medical Students - April 3, 2013 Category: Universities & Medical Training Source Type: research
